Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

Clinical trial NCT07679269 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07679269
Sponsor: Novartis Pharmaceuticals
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

PIK3CA-Related Overgrowth Spectrum (PROS)Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)

Start date: 2027-01-01
Primary completion: 2031-06-27
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.